Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024.Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.Good afternoon! Drugmakers spent big on advertisements for weight loss and diabetes treatments last year as they wrestled for dominance in the booming market for those drugs. Companies spent more than $1 billion on ads for weight loss and diabetes medicines in 2023, up 51% from the prior year, according to new data fr ...

AstraZeneca (AZN) and partner Daiichi Sankyo announced that the FDA has accepted their biologics license application (BLA) seeking approval of the antibody drug conjugate, datopotamab deruxtecan (Dato-DXd), for a breast cancer indication.The BLA is seeking approval of Dato-DXd for treating unresectable or metastatic HR+ HER2- breast cancer in patients who have received prior systemic therapy for unresectable or metastatic disease.The FDA is expected to give its decision on the BLA in the first quarter of 20 ...

AstraZeneca (AZN) announced that the FDA had approved Voydeya (danicopan) for treating paroxysmal nocturnal hemoglobinuria (PNH), a rare and chronic blood disorder.Voydeya is a first-in-class oral Factor D inhibitor, which has been approved by the FDA as an add-on to standard-of-care C5 inhibitors, Ultomiris (ravulizumab) or Soliris (eculizumab), for the treatment of extravascular hemolysis in adult patients with PNH. Ultomiris and Soliris are also marketed by AstraZeneca for treating PNH and some other rar ...

In the latest trading session, Astrazeneca (AZN) closed at $67.25, marking a -0.74% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.2%. Meanwhile, the Dow lost 0.6%, and the Nasdaq, a tech-heavy index, added 0.11%.Prior to today's trading, shares of the pharmaceutical had gained 4.88% over the past month. This has outpaced the Medical sector's gain of 2.21% and the S&P 500's gain of 3.32% in that time.Investors will be eagerly watching for the performance of Ast ...

In my view, a sure-shot way of minting money from the markets is buying and holding with patience. Of course, the idea needs to be well-researched as a first step. An important point to note is that stocks can witness price or time correction. This column focuses on stagnating blue-chip stocks (time correction) that can awaken and surge higher.It’s not uncommon for investors to lose interest in stocks that have remained sideways for an extended period. That translates into undervaluation, and the stagnating ...

Fusion Pharmaceuticals收购 - AstraZeneca宣布将收购Fusion Pharmaceuticals，以将下一代放射性药物结合物加入其癌症管线[1] - Fusion已与AstraZeneca合作开发新型TAT和组合项目，包括TAT和AstraZeneca的DDRis和免疫肿瘤学药物[4] - Fusion制造下一代放射性药物，通过精确靶向将放射性同位素直接传递到癌细胞，有望成为传统癌症治疗方案的潜在替代品[3]

The latest trading session saw Astrazeneca (AZN) ending at $65.86, denoting a +0.02% adjustment from its last day's close. This change lagged the S&P 500's 0.57% gain on the day. Meanwhile, the Dow experienced a rise of 0.83%, and the technology-dominated Nasdaq saw an increase of 0.39%.Heading into today, shares of the pharmaceutical had gained 2.46% over the past month, outpacing the Medical sector's gain of 0.13% and lagging the S&P 500's gain of 2.97% in that time.The investment community will be paying ...

AstraZeneca (AZN) announced plans to cap out-of-pocket expenses for its inhaled respiratory portfolio in the United States at $35 per month, following a similar move by rival Boehringer Ingelheim earlier this month.This cap would apply to all of AstraZeneca’s inhaled respiratory products, which include Airsupra, Bevespi Aerosphere, Breztri Aerosphere and Symbicort.However, the company plans not to start this until June 2024. The British drugmaker is one of the biggest sellers of inhalers in the United State ...

Fusion Pharmaceuticals 股价表现 - Fusion Pharmaceuticals Inc (NASDAQ:FUSN) 股价因 AstraZeneca 收购该公司的消息飙升[1] - FUSN 股价上涨97.3%，达到20.99美元，创下了21.12美元的历史新高[3] - Fusion Pharmaceuticals 股票的期权市场交易量已经是平均日交易量的40.4倍，看涨期权和看跌期权的交易量均较大[4] 评级和目标股价调整 - Wedbush 将评级下调至“中性”，Jefferies 将股票评级下调至“持有”，但两家公司都提高了目标股价[2] 空头回补情况 - 空头回补可能也是今天股价上涨的原因之一，空头利息占股票流通量的15.6%，需要近七天时间才能回补空头头寸[5]

Proactive团队 - Ian Lyall在Proactive担任Managing Editor，负责监督编辑和广播运营[1] - Proactive的新闻团队遍布全球主要金融和投资中心[2] Proactive报道范围 - Proactive专注于中小市值市场，同时也关注蓝筹公司、大宗商品和更广泛的投资故事[3] Proactive新闻内容 - Proactive团队提供关于生物技术和制药、矿业和自然资源、电池金属、石油和天然气、加密货币以及新兴数字和电动汽车技术等市场的新闻和独特见解[4]